Cargando…

NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy

BACKGROUND: NHS-IL2 (selectikine, EMD 521873, MSB0010445) consists of human NHS76 (antibody specific for necrotic DNA) fused to genetically modified human interleukin 2 (IL-2) and selectively activates the high-affinity IL-2 receptor. Based on an evolving investigational concept to prime the tumor m...

Descripción completa

Detalles Bibliográficos
Autores principales:	van den Heuvel, Michel M, Verheij, Marcel, Boshuizen, Rogier, Belderbos, José, Dingemans, Anne-Marie C, De Ruysscher, Dirk, Laurent, Julien, Tighe, Robert, Haanen, John, Quaratino, Sonia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320467/ https://www.ncbi.nlm.nih.gov/pubmed/25622640 http://dx.doi.org/10.1186/s12967-015-0397-0

Ejemplares similares

The immunocytokine NHS-IL12 as a potential cancer therapeutic
por: Fallon, Jonathan, et al.
Publicado: (2014)

A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients
por: Oberije, Cary, et al.
Publicado: (2015)

Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial
por: Compter, Inge, et al.
Publicado: (2020)

NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models
por: Xu, Chunxiao, et al.
Publicado: (2021)

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma
por: Bharathy, Narendra, et al.
Publicado: (2019)

Challenges in the target volume definition of lung cancer radiotherapy
por: Mercieca, Susan, et al.
Publicado: (2021)

Defining the Pharmacodynamic Profile and Therapeutic Index of NHS-IL12 Immunocytokine in Dogs with Malignant Melanoma
por: Paoloni, Melissa, et al.
Publicado: (2015)

NHS-IL12, a Tumor-Targeting Immunocytokine
por: Greiner, John W, et al.
Publicado: (2021)

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma
por: Strauss, Julius, et al.
Publicado: (2023)

Mechanistic rationales for combining immunotherapy with radiotherapy
por: Chi, Alexander, et al.
Publicado: (2023)

Biomarkers of Radiotherapy-Induced Immunogenic Cell Death
por: Vaes, Rianne D. W., et al.
Publicado: (2021)

Handgrip weakness, low fat‐free mass, and overall survival in non‐small cell lung cancer treated with curative‐intent radiotherapy
por: Burtin, Chris, et al.
Publicado: (2020)

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
por: Mittica, Gloria, et al.
Publicado: (2017)

Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence
por: Mecca, Carmen, et al.
Publicado: (2018)

A Phase I Study of Concurrent Individualized, Isotoxic Accelerated Radiotherapy and Cisplatin–Vinorelbine–Cetuximab in Patients With Stage III Non–Small-Cell Lung Cancer
por: Dingemans, Anne-Marie C., et al.
Publicado: (2014)

Early body weight loss during concurrent chemo-radiotherapy for non-small cell lung cancer
por: Op den Kamp, Céline M. H., et al.
Publicado: (2014)

Accuracy of deformable image registration for contour propagation in adaptive lung radiotherapy
por: Hardcastle, Nicholas, et al.
Publicado: (2013)

The Authors reply: Comment on: “Handgrip weakness, low fat‐free mass, and overall survival in non‐small cell lung cancer treated with curative‐intent radiotherapy” by Burtin et al.
por: Burtin, Chris, et al.
Publicado: (2021)

Pharmacological Rationale for Targeting IL-17 in Asthma
por: Rahmawati, Siti Farah, et al.
Publicado: (2021)

No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone
por: Peterse, Elisabeth F. P., et al.
Publicado: (2016)

PARP Inhibitors in Prostate Cancer–the Preclinical Rationale and Current Clinical Development
por: Virtanen, Verneri, et al.
Publicado: (2019)

Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data
por: Giles, Thomas D., et al.
Publicado: (2017)

Preclinical model for lumbar interbody fusion in small ruminants: Rationale and guideline
por: Duits, Anneli, et al.
Publicado: (2022)

Fully competent dendritic cells as inducers of T cell anergy in autoimmunity
por: Quaratino, S, et al.
Publicado: (2001)

A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas
por: Hidalgo, Manuel, et al.
Publicado: (2022)

An overview of the published and running randomized phase 3 clinical results of radiotherapy in combination with immunotherapy
por: Vanneste, Ben G. L., et al.
Publicado: (2021)

The rationale for MR-only treatment planning for external radiotherapy
por: Jonsson, Joakim, et al.
Publicado: (2019)

Real-World Evaluation of Modern Adjuvant Radiotherapy in Women with Stage IB Endometrial Cancer
por: Chen, Jenny Ling-Yu, et al.
Publicado: (2021)

Immunotherapy as sensitizer for local radiotherapy
por: Vanneste, Ben G.L., et al.
Publicado: (2020)

Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer
por: Vlayen, Joan, et al.
Publicado: (2015)

Anti-Angiogenic Treatment in Pseudomyxoma Peritonei—Still a Strong Preclinical Rationale
por: Andersson, Yvonne, et al.
Publicado: (2021)

Perioperative immunotherapy in stage IB-III non-small cell lung cancer: a critical review of its rationale and considerations
por: Sim, Jae Kyeom, et al.
Publicado: (2023)

Thoughts on the NHS
por: Read, M. D.
Publicado: (1991)

The NHS Transformed
por: McNicol, Martin
Publicado: (1993)

Health in the NHS
por: Waldron, H A
Publicado: (1996)

The College and the NHS
por: McDonald, W Ian
Publicado: (1998)

Modelling of IBS
por: Zampetakis, Michail
Publicado: (2019)

MR-Guided Radiotherapy: The Perfect Partner for Immunotherapy?
por: Hörner-Rieber, Juliane, et al.
Publicado: (2021)

AB004. Radiotherapy for thymic epithelial tumors: what is the optimal dose?—a systematic review
por: Angrisani, Antonio, et al.
Publicado: (2022)

A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma
por: Lewin, J, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_krlmkdkvgb0s0s94lnetae3cuu